-
These two stocks did not join the market to new heights of all time.
-
Both companies are the leaders of their niches.
-
I think these are the classic examples of Premium companies selling fair prices.
-
10 shares we like more than Zoeti ›
S&P 500 Continue to new heights of all time, so far in 2025. Returning the total return of 15.2%. However, most of this run comes from “amazing seven” and other mass technology stocks that have a major impact on the index. In the meantime, despite the fact that the market -looking state, there are many promising opportunities.
Today, I will look at a couple of niches leading health care actions that have not yet joined the current market Bull running, so they are two of my favorite shares that need to be bought now.
Zoeto (NYS: ZTS) is the best dog and livestock health care dog for medication, vaccines, diagnostics and even more eight animal species to owners worldwide. Zoetis, driven by the 17 most popular drugs earning more than $ 100 million, is a well -diversified innovation machine.
However, from 2021. By the end of the 19th century, the company’s stocks decreased by 40%, after a new high height of all time was reached during pandemia.
Worse, Zoeti sold medicines from the most promising growth area-osteoarthritis (OA) for medical dogs and cats, decreased by 4% per year, extending the sale. This decrease in sales may seem anxiety as Zoetis recently 2023 and 2022. Adapted to Liblala (dogs) and Solensia (cats). However, investors should not panic yet.
First, according to the leadership, there are more than 18 million dogs in the US, whose OA is untreated compared to just 1 million, helped by Lible. In this market, Zoeti is still very early innive. Second, 75% of former or current Lible customers were “very or extremely satisfied” with the results they saw, so it should be solid.
However, veterinarians are asking for more data from Zoeti to help them sell Liblela and Solensia. Specifically, they want to show a greater degree of safety and efficacy to the company’s monoclonal antibody proposals compared to existing non -steroidal anti -inflammatory drugs. With the launch of phase 4 and many other third -party analyzes, I hope to emphasize its excellent results, Zoetis plans to start the results until the fourth quarter and in 2026. Positive results of these studies could re -start sales growth in the OA market, as the company could make a more clear offer of its value to both veterinarians.
Since 2013 It grows 8% per year – compared to wider growth of the animal health care industry – 5% – I am convinced that Zoetis’ ability to innovate and successfully perform for a long time. When the company browses through this temporary, short -term rude correction, Zoetis remains one of my favorite purchases, selling small decades and small prices and power (p/e) 25.
UFP technology (Nasdaq: UFPT) There is a contract development and production organization working together with 26 of the 30 largest manufacturers of medical original equipment (OEM). UFP cooperates with its OEM customers:
-
the possibilities of design, ideas and engineering
-
Material experience including access to certain exclusive medical degree items
-
Certified accuracy production
-
Ability to scaling
The products he creates with his customers ranges from the largest business lines, surgical (RAS) curtains, to medical and surgical beds, without the needle injection port cleaning and revascularization facilities. Simply put, UFP is dominated by many unique niches in the medical device industry. Most importantly, most of the company’s sales are one -off, one patient’s products that provide recurrent, predictable sales.
After purchasing 22 companies in their history, including nine in the last five years, the UFP is a masterful serial purchased person and constantly wants to expand into adjacent verticals.
Managed by double-digit growth rates expected from RAS RAS industry and new sales from acquisitions, the leadership believes that UFP sales will grow by 15%over the next three to five years. After a decade, when income and net income increased 16% and 30% per year, I do not intend to doubt their ability to do so.
Since 2000 72 Bowpper UFP is one of my favorite shares that can now be bought 23 times as it grows with its Juggernaut customers, such as Juggernaut customers Intuitive surgical;
Consider this before buying a Zoeti reserves:
Motley Fool Stock Advisor A team of analysts just found what they think is 10 best stocks Investors buy now … and “Zoetis” was not one of them. 10 stocks that reduced the incision can return the monster in the coming years.
Consider when Netflix This list consisted of 2004. December 17th … If you have invested $ 1,000 during our recommendation, at our recommendation, You would have $ 621,976!* Or when Nvidia Made this list in 2005. April 15 … If you have invested $ 1,000 during our recommendation, at our recommendation, You would have $ 1,150 085!*
Now it is worth mentioning Share advisor The average return is 1 058%-S&P 500, compared to 191 %, the advantage of the market compression. Don’t miss the latest top 10 list that can be purchased when you log in to login Share advisor;
See. 10 stocks »
*The stock advisor returns from 2025. September 29th
Josh Kohn-Lindquist has positions in intuitively surgical, UFP technology and “zoetis”. Motley fool is a position and recommends intuitive surgical and zoetide. Motley fool recommends UFP technology. The Motley fool has a disclosure policy.
My 2 favorite shares to buy right now, originally released by The Motley Fool
